# Drug Use Investigation for REVOLADE (ITP)

> **NCT01416311** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 5797 (actual)

## Conditions studied

- Purpura, Thrombocytopaenic, Idiopathic

## Interventions

- **DRUG:** Eltrombopag

## Key facts

- **NCT ID:** NCT01416311
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12-21
- **Primary completion:** 2020-10-16
- **Final completion:** 2020-10-16
- **Target enrollment:** 5797 (ACTUAL)
- **Last updated:** 2020-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01416311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01416311, "Drug Use Investigation for REVOLADE (ITP)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01416311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*